Monday, May 23, 2016

BRIEF-Ipsen SA says Exelixis Inc reported positive top-line results from Cabosun phase 2 trial of Cabozantinib

* reported positive top line results from Cabosun phase 2

trial of Cabozantinib in patients with untreated advanced renal

cell carcinoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)